Playback speed
10 seconds
ESMO 2023 Insights: "The NICHE-3 Study on Neoadjuvant Nivo + Relatlimab (anti-LAG3) in Locally Advanced MMR-Deficient Colon Cancers"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Yara Verschoor
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Yara Verschoor
112 views
October 31, 2023
Login to view comments.
Click here to Login